Edoxaban

Catalog No.S4429 Batch:S442901

Print

Technical Data

Formula

C24H30ClN7O4S
Molecular Weight 548.06 CAS No. 480449-70-5
Solubility (25°C)* In vitro DMSO 10 mg/mL (18.24 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Edoxaban (DU-176b, Savaysa), an antithrombotic agent, is a selective, potent and orally active inhibitor of factor Xa (FXa) with Ki of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively.
Targets
Factor Xa [1]
(Cell-free assay)		 Prothrombinase [1]
(Cell-free assay)
0.561 nM(Ki) 2.98 nM(Ki)
In vitro

The dual split protein (DSP) assay using Calu-3 cells is performed in the presence of various anticoagulants, including edoxaban.[2]

Protocol (from reference)

Cell Assay:

[2]
  • Cell lines

    Calu-3 cells

  • Concentrations

    --

  • Incubation Time

    --

  • Method

    For the DSP assay using Calu-3 or H3255 cells, target cells were seeded in 384-well plates (2 × 104 cells/50 μL) one day before the assay. Two hours before the DSP assay, cells were treated with 6 μM EnduRen. One microliter of each protease inhibitor or anticoagulant dissolved in DMSO was added to the 384-well plates with 9 μL of culture medium. Next, 40 μL of single cell suspension (effector cells) was added to the wells using a Multidrop dispenser.

    (Data sourced from selleck products)

Selleck's Edoxaban has been cited by 5 publications

Tissue factor-induced fibrinogenesis mediates cancer cell clustering and multiclonal peritoneal metastasis [ Cancer Lett, 2023, 553:215983] PubMed: 36404569
OKL-1111, A modified cyclodextrin as a potential universal reversal agent for anticoagulants [ Thromb Res, 2023, 227:17-24] PubMed: 37207560
Unveiling the complex effects of direct oral anticoagulants on dilute Russell's viper venom time assays [ J Thromb Haemost, 2020, 18(8):1866-1873] PubMed: 32294291
Unveiling the complex effects of direct oral anticoagulants on dilute Russell's viper venom time assays [ Journal of Thrombosis and Haemostasis, 2020, 1866-1873] PubMed: None
The anticoagulant nafamostat potently inhibits SARS-CoV-2 infection in vitro: an existing drug with multiple possible therapeutic effects [ bioRxiv, 2020, 10.1101/2020.04.22.054981] PubMed: None

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.